News

A cross-disciplinary team of surgeons and bioengineers from Vanderbilt University, Columbia University, Stanford University, New York-Presbyterian Hospital, State University of New York Downstate Medical Center, and Xylyx Bio collaborated to develop a new technique called ‘xenogeneic cross-circulation’, which involves temporarily connecting a human donor lung to a live pig to support and resuscitate the human organ outside the body.

The Journal of Heart and Lung Transplantation recently published the peer-reviewed manuscript. The results showed the potential pf the technique to increase the number of organs available for transplant.

Researchers at the University of Illinois applied Xylyx Bio’s IN SITE Metastasis Kit to evaluate a cancer therapeutic. Molecular Cancer Research, a journal of the American Association for Cancer Research, recently published the peer-reviewed manuscript. The results showed that dietary interventions may increase the efficacy of treatment for breast cancer metastases.

Read the Publication!

Watch the Xylyx Bio Metastasis Webinar!

Xylyx Bio has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of an anti-fibrotic drug testing platform that will help scientists discover and test drug candidates for idiopathic pulmonary fibrosis (IPF).

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research.

Xylyx Bio launched VIVIQ Skin Health, a prestige skincare brand with the world’s first and only skincare product powered by Matrikynes® biotechnology, a clinically proven blend of extracellular matrix peptides designed to bring clinic-worthy results to consumer skincare.

New  York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates, today announced positive preliminary results, reaching a key milestone in their partnership to develop more physiologically relevant in vitro cellular models for cell-based assays in oncology.

Xylyx Bio now offers specialized contract R&D services based on its highly predictive IN MATRICO™ platform. Xylyx Bio’s custom assays incorporate human disease-specific extracellular matrix (ECM) substrates combined with clinically relevant informatics to better represent human biology and reliably de-risk drug discovery through early efficacy signals that simultaneously reduce costs and development time.

Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH.

New  York-based Xylyx Bio, a leader in predictive disease models and tissue-specific extracellular matrix (ECM) products, and Cell&Soft SAS, a French biotech company specializing in innovative soft cell culture plates,today announced a strategic partnership for the development of in vitro cellular models for cell-based assays in oncology.

Lung extracellular matrix (ECM) is implicated in the pathogenesis and progression of lung fibrosis. Current preclinical lung fibrosis models do not incorporate lung ECM, and therefore lack the defining part of the fibrotic lung disease environment.

In this webinar, we describe the paradigm shift in drug discovery from ‘in vitro’ to ‘in matrico’, and present our Human Lung Fibrosis platform for disease modeling and compound testing. Leveraging human fibrotic lung ECM and corresponding clinical data, the platform increases the relevance of cell-based assays and enables lung fibrosis modeling with clinical context to accelerate drug development.